Monitoring conceptual development with text mining technologies: CONSPECT

This paper evaluates CONSPECT, a service that analyses states in a learner’s conceptual development. It combines two technologies – Latent Semantic Analysis to analyse text and Network Analysis (NA) to provide visualisations – into a technique called Meaningful Interaction Analysis (MIA). CONSPECT was designed to help both online learners and their tutors monitor their conceptual development. This paper reports on the validation experiments undertaken to determine how well LSA matches first year medical students in clustering concepts and in annotating text. The validation used several techniques, including card sorting and Likert scales. CONSPECT produces almost ‘peer’ quality results and what remains to be tested is whether it improves with more advanced learners. One of the experiments showed an average 0.7 correlation between humans and CONSPECT

D2.4. Building a Personal Learning Environment with Language-Technology-based Widgets: Services v2 - integrated thread

Hoisl, B., Haley, D., Wild, F., Anastasiou, L., Buelow, K., Koblische, R., Burek, G., Loiseau, M., Markus, T., Rebedea, T., Drachsler, H., Kometter, H., Westerhout, E., & Posea, V. (2010). D2.4. Building a Personal Learning Environment with Language-Technology-based Widgets: Services v2 - integrated thread. LTfLL-project.This deliverable reports on the results achieved by the LTfLL work packages in their efforts toward interoperability of the LTfLL tools and services. There are two aspects: one is the pedagogical utility of achieving interoperability; the other aspect involves the technical features. The technical basis of the interoperability is to use Wookie widgets in Elgg and is thoroughly described here. Finally, the deliverable provides details and screen shots of each widget for each LTfLL service embedded in the Elgg environment.The work on this publication has been sponsored by the LTfLL STREP that is funded by the European Commission's 7th Framework Programme. Contract 212578 [http://www.ltfll-project.org

Using language technologies for monitoring conceptual development

This paper describes and evaluates CONSPECT (from concept inspection), an application that analyses states in a learner’s conceptual development. It was designed to help online learners and their tutors monitor conceptual development and also to help reduce the workload of tutors monitoring a learner’s conceptual development. CONSPECT combines two technologies – Latent Semantic Analysis (LSA) and Network Analysis (NA)into a technique called Meaningful Interaction Analysis (MIA). LSA analyses the meaning in the textual digital traces left behind by learners in their learning journey; NA provides the analytic instrument to investigate (visually) the semantic structures identified by LSA. This paper describes the validation activities undertaken to show how well LSA matches first year medical students in 1) grouping similar concepts and 2) annotating text

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

PurposeABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735) in patients with relapsed/refractory multiple myeloma (RRMM). Herein, we report safety and efficacy outcomes of this phase I dose escalation/expansion study.MethodsPatients with RRMM (≥ three prior lines including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody) were eligible. ABBV-383 was administered intravenously over 1-2 hours once every 3 weeks, without any step dosing. A 3 + 3 design with backfilling for dose escalation was used (intrapatient escalation to highest safe dose permitted) followed by initiation of dose expansion.ResultsAs of January 8, 2022, 124 patients (dose escalation [0.025-120 mg], n = 73; dose expansion [60 mg], n = 51) have received ABBV-383; median age was 68 years (range, 35-92 years). The most common hematologic treatment-emergent adverse events (TEAEs) were neutropenia (all grades: 37%) and anemia (29%). The most common nonhematologic TEAEs were cytokine release syndrome (57%) and fatigue (30%). Seven deaths from TEAEs were reported with all considered unrelated to study drug by the investigator. For all efficacy-evaluable patients (n = 122; all doses), the objective response rate (ORR) was 57% and very good partial response (VGPR) or better (≥ VGPR) rate was 43%. In the 60 mg dose expansion cohort (n = 49), the ORR and ≥ VGPR rates were 59% and 39%, respectively; and in the ≥ 40 mg dose escalation plus dose expansion cohorts (n = 79) were 68% and 54%, respectively.ConclusionABBV-383 in patients with RRMM was well tolerated with an ORR of 68% at doses ≥ 40 mg. This novel therapy's promising preliminary antitumor activity in heavily pretreated patients warrants further clinical evaluation